Your browser doesn't support javascript.
loading
Cancer immune escape: the role of antigen presentation machinery.
Kallingal, Anoop; Olszewski, Mateusz; Maciejewska, Natalia; Brankiewicz, Wioletta; Baginski, Maciej.
Afiliação
  • Kallingal A; Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland. anoop.kallingal@pg.edu.pl.
  • Olszewski M; Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland.
  • Maciejewska N; Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland.
  • Brankiewicz W; Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland.
  • Baginski M; Department of Medical Genetics, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
J Cancer Res Clin Oncol ; 149(10): 8131-8141, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37031434
The mechanisms of antigen processing and presentation play a crucial role in the recognition and targeting of cancer cells by the immune system. Cancer cells can evade the immune system by downregulating or losing the expression of the proteins recognized by the immune cells as antigens, creating an immunosuppressive microenvironment, and altering their ability to process and present antigens. This review focuses on the mechanisms of cancer immune evasion with a specific emphasis on the role of antigen presentation machinery. The study of the immunopeptidome, or peptidomics, has provided insights into the mechanisms of cancer immune evasion and has potential applications in cancer diagnosis and treatment. Additionally, manipulating the epigenetic landscape of cancer cells plays a critical role in suppressing the immune response against cancer. Targeting these mechanisms through the use of HDACis, DNMTis, and combination therapies has the potential to improve the efficacy of cancer immunotherapy. However, further research is needed to fully understand the mechanisms of action and optimal use of these therapies in the clinical setting.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apresentação de Antígeno / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apresentação de Antígeno / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article